TrialDiabetes & vascular disease research2016

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.

Ian J Neeland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.